Researchers funded by Health Data Research UK (HDR UK) have developed a new tool to help doctors and pharmacists identify older patients at risk of delirium and serious falls associated with taking multiple anticholinergic medications. Anticholinergic medications are widely used…
Researchers funded by Health Data Research UK (HDR UK) have developed a new tool to help doctors and pharmacists identify older patients at risk of delirium and serious falls associated with taking multiple anticholinergic medications. Anticholinergic medications are widely used…
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT. The investigational CD38-targeted immuno-PET tracer zirconium 89 (89Zr) deferoxamine (DFO)–daratumumab (Darzalex) detected active multiple myeloma in some patients…
My name is Mateo Mejia, I am an assistant professor of medicine at Weill Cornell Medicine and I work with the multiple myeloma and cell therapy group. We discussed today, or debated more so, the role of treatment in high-risk…
— "While no imaging modality is perfect, this adds a new tool," says researcher A novel CD38-targeted immuno-PET tracer could help detect multiple myeloma in some patients with no signs of disease, according to results from a phase II trial. For…
At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction. Ciltacabtagene autoleucel (Carvykti) is approved after at least 1 prior line of therapy for lenalidomide-refractory multiple myeloma, based on the…
November 5, 2026 02:00 PM EST Medical Imaging · Diagnostic Imaging · Oncologic Imaging · Artificial Intelligence November 4, 2026 · News Release Multiple myeloma is characterized by its growth in the bone marrow and potential spread to various body locations. Traditional imaging techniques and newer blood tests are…
Novo Nordisk Receives FDA Approval for Children's Diabetes Treatment Novo Nordisk has expanded access to once-weekly pediatric insulin following FDA approval of Awiqli for children aged 10 and older with type 2 diabetes. The long-acting treatment replaces seven weekly basal insulin injections…
ISB 2001 (ABBV-2001) Oral Presentation (abstract link): First- and only-in-class CD38 x BCMA x CD3 trispecific T-cell engager ISB 2001 (ABBV-2001): Updated Phase 1 (TRIgnite-1) study data demonstrate robust efficacy and tolerability in relapsed/refractory multiple myeloma (RRMM) Presenter: Binod Dhakal, M.D., Medical College of Wisconsin…
These findings describe a broader population than the 80 patients meeting the FDA-approved prior-treatment criteria, whose response rate was 70%. The trial excluded previous BCMA-directed CAR T-cell therapy or bispecific T-cell engager exposure, limiting extrapolation to BCMA retreatment.² Administration logistics helped explain…
Drugs and Devices in Longevity: the news, the names and what changed.
An article joins this feed when it matches these terms. Each one is also a search of its own.